Everolimus (Certican) in combination with neoral in pediatric renal transplant recipients: interim analysis after 3 months.
Vester
U
U
Pediatric Nephrology, University Esssen, Essen, Germany. udo.vester@medizir.uni-essen.de
Kranz
B
B
Wehr
S
S
Boger
R
R
Hoyer
P F
PF
D000293:Adolescent; D002648:Child; D016572:Cyclosporine / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005006:Ethnicity; D000068338:Everolimus; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007166:Immunosuppressive Agents / Q000493:pharmacokinetics / Q000627:therapeutic use*; D016030:Kidney Transplantation / Q000276:immunology*; D008297:Male; D011241:Prednisone / Q000627:therapeutic use; D020123:Sirolimus / Q000031:analogs & derivatives / Q000493:pharmacokinetics / Q000627:therapeutic use*; D013997:Time Factors
D007166:Immunosuppressive Agents; D016572:Cyclosporine; D000068338:Everolimus; D011241:Prednisone; D020123:Sirolimus